glp 1/gip agonist Main physiological actions of the dual GIP and GLP-1 Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic

Economic growth in developed economies typically supports higher healthcare spending, facilitating the adoption of relatively expensive GLP-1 receptor agonists

Specific warnings include the risk of aspiration for patients, the need for patients to inform their anaesthetist they are taking these medications, and for anaesthetists to consider the heightened risk of aspiration and to manage such patients accordingly

Strain, W

Tirzepatide became the first dual GLP/GLP-1 receptor agonist to gain FDA approval for treating T2DM in 2022 and obesity in 2023 [ Table 2 ]

Ann Pharmacother (2017) 51:4019

Moreover, GIP has been found to boost glucose uptake by improving insulin sensitivity in adipocytes (176, 177), while tirzepatide has been demonstrated to enhance insulin sensitivity and promote glucose disposal in white adipose tissue in Glp-1r-null mice (178), further supporting a direct effect of GIP on adipose tissues